Federated Hermes Inc. Lowers Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

Federated Hermes Inc. cut its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 18.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 907,200 shares of the company's stock after selling 202,300 shares during the period. Federated Hermes Inc. owned about 0.77% of Guardant Health worth $24,540,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of GH. CWM LLC raised its stake in Guardant Health by 137.1% in the 3rd quarter. CWM LLC now owns 984 shares of the company's stock valued at $29,000 after acquiring an additional 569 shares during the period. AE Wealth Management LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $572,000. SG Americas Securities LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $818,000. Mach 1 Financial Group LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $565,000. Finally, Handelsbanken Fonder AB raised its stake in Guardant Health by 7.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 122,441 shares of the company's stock valued at $3,629,000 after acquiring an additional 8,341 shares during the period. 92.60% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Kumud Kalia acquired 2,187 shares of the firm's stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares in the company, valued at $226,706.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GH. The Goldman Sachs Group reduced their target price on Guardant Health from $32.00 to $28.00 and set a "buy" rating for the company in a report on Monday, April 15th. JPMorgan Chase & Co. reduced their target price on Guardant Health from $60.00 to $45.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Piper Sandler reduced their target price on Guardant Health from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, February 26th. Canaccord Genuity Group cut their price objective on Guardant Health from $50.00 to $45.00 and set a "buy" rating for the company in a report on Friday, February 23rd. Finally, Guggenheim reissued a "neutral" rating on shares of Guardant Health in a report on Friday, April 5th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of "Moderate Buy" and an average price target of $40.40.

Guardant Health Trading Up 9.5 %

Shares of Guardant Health stock traded up $1.52 during midday trading on Monday, reaching $17.59. 1,962,892 shares of the company's stock traded hands, compared to its average volume of 1,897,286. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The company has a market cap of $2.14 billion, a PE ratio of -4.11 and a beta of 0.87. The stock has a 50 day moving average of $19.10 and a 200-day moving average of $23.11. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $41.06.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.65). The business had revenue of $155.05 million for the quarter, compared to the consensus estimate of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. As a group, equities analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.